InnFocus has reached its goal of enrolling 75 patients in a Phase I clinical study for its MicroShunt glaucoma eye-drainage implant.
The device is used to help reduce pressure within the eye in patients with glaucoma. The product is intended to be an alternative to traditional glaucoma surgery.
InnFocus said it expects to enter the final stage of the Phase I trial later this year.
"Achieving this milestone is an important step in our goal to provide a safe, effective, sustainable, and easy to perform alternative for the surgical treatment of glaucoma," said InnFocus CEO Russ Trenary, in a release. "The rate of treatment volume in the study has increased substantially giving us great confidence we will complete the final phase quickly."
MicroShunt received CE Mark clearance in January 2012. InnFocus is seeking to have the product approved in the U.S. for the treatment of Primary Open-Angle Glaucoma. The company has also been testing the product in conjunction with cataract surgery.